383433-14-5

Upstream product

• 98556-31-1 4-chloro-6-iodoquinazoline 
• 92136-39-5 N-tert-Butoxycarbonyl-1-amino-3-propyne 
• 537705-06-9 3-(2-methyl-4-aminophenoxy)-6-methylpyridine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1121-78-4 5-Hydroxy-2-methylpyridine 
• 13290-74-9 1-chloro-2-methyl-4-nitrobenzene 
• 697299-78-8 2-methyl-5-(2-methyl-4-nitrophenoxy)pyridine 
• 5326-47-6 2-amino-5-iodobenzoic acid 
• 16064-08-7 6-iodo-4-hydroxyquinazoline 
• 537705-10-5 (6-iodoquinazolin-4-yl)-[3-methyl-4-(6-methylpyridin-3-yloxy)phenyl]amine hydrochloride 

Downstream Products

• 383432-38-0 (E)-2-methoxy-N-(3-{4-[3-methyl-4-(6-methylpyridin-3-yloxy)phenylamino]quinazolin-6-yl}allyl)acetamide 
• 383434-55-7 E-[6-(3-amino-propenyl)-quinazolin-4-yl]-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenyl]-amine 
• 383432-25-5 [6-(3-amino-prop-1-ynyl)-quinazolin-4-yl]-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenyl]-amine 

Relevant academic research and scientific papers

COMBINATIONS OF ERBB2 INHIBITORS WITH OTHER THERAPEUTIC AGENTS IN THE TREATMENT OF CANCER

This invention relates to a method of treatment of cancer with a combination of an additional therapeutic agent in mammals. This invention also relates to a kit useful in the treatment of abnormal cell growth in mammals, especially humans.

Evaluation of kilogram-scale Sonagashira, Suzuki, and Heck coupling routes to oncology candidate CP-724,714

The synthesis of the anti-cancer compound 2-methoxy-N-(3-{4-[3-methyl-4-(6- methyl-pyridin-3-yloxy)phenylamino]quinazolin-6-yl}-E-allyl)acetainide (CP-724,714) (1) on multikilogram scale using several different synthetic routes is described. Application of the Sonogashira, Suzuki, and Heck couplings to this synthesis was investigated to identify a safe, environmentally friendly, and robust process for the production of this drug candidate. A convergent and selective synthesis of the candidate was identified which utilizes a Heck coupling of a protected allylamine to install the critical olefin.

Selective erbB2 inhibitor/anti-erbB antibody combinations in the treatment of cancer

This invention relates to a method of treatment of cancer with a combination of an erbB2 ligand and an antibody, in mammals. More particularly, this invention relates to a method of treating cancer by administering an erbB2 ligand in combination with an erbB antibody. This invention also relates to a kit useful in the treatment of abnormal cell growth in mammals, especially humans.

Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors

Cyanoguanidine quinazoline and cyanoamidine quinazolamine derivatives that are useful in the treatment of hyperproliferative diseases are disclosed. Methods of treating hyperproliferative diseases in mammals are also disclosed.